Current Report Filing (8-k)
August 12 2021 - 4:57PM
Edgar (US Regulatory)
0001819576
false
0001819576
2021-08-12
2021-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 12, 2021
LIQUIDIA CORPORATION
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-39724
|
85-1710962
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
419 Davis Drive, Suite 100, Morrisville, North Carolina
|
27560
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (919) 328-4400
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock
|
LQDA
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On August 12, 2021, Liquidia Corporation,
a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Patent Trial and Appeal
Board has instituted inter partes review against U.S. Patent No. 10,716,793, owned by United Therapeutics Corporation and listed
in the Orange Book for Tyvaso® (treprostinil). A copy of the press release is filed as Exhibit 99.1 and is incorporated by reference
into this Item 8.01.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
August 12, 2021
|
Liquidia Corporation
|
|
|
|
By:
|
/s/ Michael Kaseta
|
|
|
Name:
|
Michael Kaseta
|
|
|
Title:
|
Chief Financial Officer
|
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Sep 2023 to Sep 2024